MTOR and leukemia: Notably, rocaglates with a pyrimidinone ring fusion (RPs) stand out as a subgroup that exclusively targeted leukemia cells and not healthy cells, with individual members displaying exceptional ability to activate intrinsic DNA damage responses that lead to the selective destruction of malignant cells while retaining mechanistic target of rapamycin (mTOR) pathway activity.